CytoMed Therapeutics Reports Rise in Collaborations

Ticker: GDTC · Form: 6-K · Filed: Dec 5, 2024 · CIK: 1873093

Cytomed Therapeutics LTD 6-K Filing Summary
FieldDetail
CompanyCytomed Therapeutics LTD (GDTC)
Form Type6-K
Filed DateDec 5, 2024
Risk Levellow
Pages1
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: collaboration, pharmaceuticals, foreign-private-issuer

TL;DR

CytoMed Therapeutics sees a surge in domestic and international partnerships.

AI Summary

CytoMed Therapeutics Limited, formerly CytoMed Therapeutics Pte. Ltd., filed a Form 6-K on December 5, 2024. The company, incorporated in Singapore with its principal executive office at 1 Commonwealth Lane, is reporting a significant rise in domestic and international collaborations. This filing is made under the Securities Exchange Act of 1934.

Why It Matters

An increase in collaborations suggests potential growth opportunities and expanded reach for CytoMed Therapeutics' pharmaceutical products.

Risk Assessment

Risk Level: low — This filing is a routine report of foreign private issuer information and does not contain specific financial or operational risks.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose is to report a significant rise in domestic and international collaborations by CytoMed Therapeutics Limited.

When was CytoMed Therapeutics Limited's name changed from CytoMed Therapeutics Pte. Ltd.?

The date of the name change was July 16, 2021.

Where is CytoMed Therapeutics Limited's principal executive office located?

The principal executive office is located at 1 Commonwealth Lane, #08-22, Singapore 149544.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

What industry does CytoMed Therapeutics Ltd. operate in?

CytoMed Therapeutics Ltd. operates in the Pharmaceutical Preparations industry (SIC code 2834).

Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 16.8 · Accepted 2024-12-05 17:00:28

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CytoMed Therapeutics Limited Date: December 5, 2024 By: /s/ CHOO Chee Kong CHOO Chee Kong Director and Chairman

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing